Abstract: The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.
Abstract: The present disclosure provides, inter alia, engineered microbes expressing recombinant LEKTI domains that are effective to treat or ameliorate the symptoms of Netherton Syndrome. In certain embodiments, compositions, methods, and kits are provided comprising LEKTI domain expressing microbes.
Type:
Grant
Filed:
June 15, 2018
Date of Patent:
October 3, 2023
Assignee:
Azitra Inc
Inventors:
Travis Michael Whitfill, Azim Momin Munivar
Abstract: The present disclosure provides recombinant Staphylococcus bacterium (e.g. S. epidermidis) that are dependent on D-alanine for growth. In one aspect, the disclosure features a recombinant Staphylococcus bacterium comprising two inactivated alanine racemase genes (?alr1?alr2); and an inactivated D-alanine aminotransferase (dat) gene. In another aspect, the disclosure features a method of making the recombinant Staphylococcus bacterium.
Type:
Grant
Filed:
January 4, 2019
Date of Patent:
June 22, 2021
Assignee:
Azitra Inc
Inventors:
Travis Michael Whitfill, Ming-De Deng, David Richard Dodds, Alexander Tikhonov
Abstract: The present disclosure provides, inter alia, treating and/or preventing cancer and symptoms thereof, using recombinant LEKTI domains and microbes genetically modified to express one or more LEKTI protein domains encoded by one or more SPINK genes. In certain embodiments, compositions, methods, and kits are provided comprising recombinant LEKTI domains and microbes genetically modified to express one or more LEKTI protein domains encoded by one or more SPINK genes.
Abstract: The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
Type:
Grant
Filed:
May 28, 2015
Date of Patent:
July 7, 2020
Assignee:
Azitra Inc
Inventors:
Azim Momin Munivar, Travis Michael Whitfill